Drug intelligence / Profile preview

hyoscine-n-butylbromide + ondansetron

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a **combination drug** consisting of **hyoscine-n-butylbromide** (also known as hyoscine butylbromide or scopolamine butylbromide) and **ondansetron**. - **Hyoscine-n-butylbromide** is an anticholinergic and antispasmodic agent used to relieve pain and discomfort from smooth muscle spasms in the gastrointestinal, biliary, or genitourinary tracts. It acts by blocking muscarinic acetylcholine receptors on smooth muscle cells, leading to muscle relaxation[2][4][6]. - **Ondansetron** is a selective serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by chemotherapy, radiation, or surgery. It blocks serotonin from stimulating the 5-HT3 receptors in the gut and brain, thereby inhibiting the vomiting reflex[1][5][7]. The combination may be used in clinical practice to manage gastrointestinal symptoms where both smooth muscle spasm and nausea/vomiting are present, although standard fixed-dose products are uncommon.

Other names
hyoscine-n-butylbromide + ondansetronscopolamine butylbromide + ondansetron
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on hyoscine-n-butylbromide + ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hyoscine-n-butylbromide + ondansetron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call